Jason Napodano Blog | Talkmarkets | Page 1
Biopharma Stock Analyst & Consultant

I provide sponsored equity research on small-cap biopharma stocks.

All Contributions

Latest Posts
1 to 16 of 54 Posts
1 2 3 4
BriaCell Clinical Update Shows Progress With Breast Cancer Program
BriaCell Therapeutics Corp. continues to enroll patients in its Phase 1/2a clinical trial of BriaVax for the treatment of advanced breast cancer.
Iomab-B Makes Actinium Pharma A Rare And Exciting Investment Opportunity
BMT is one of the fastest growing hospital procedures according to AHRQ; US Dept. of HHS. Iomab-B offers a better solution - cheaper, faster, safer, and more effective - than the current standard of care.
HedgePath Granted Type C Meeting With FDA
edgePath Pharmaceuticals, Inc. (HPPI) announced the company has been granted a Type C meeting with the U.S. FDA to discuss the interim results from the company's Phase 2b clinical study of SUBA-Cap.
With Cash In Hand, Focus For MabVax Turns To The Clinical Program
This morning, MabVax Therapeutics closed a public offering of $4.1 million in cash. The company offered 1.343 million shares.
Matinas Well Positioned For June Data Read Outs
Matinas BioPharma Holdings, Inc. reported financial results for the first quarter ending March 31, 2017. The company also provided an update on anti-infective drug candidates, MAT2203 and MAT2501.
Continued Progress, Promise With Oryzon's Pipeline
Oryzon is focused on developing epigenetic-based therapies and personalized drugs from its proprietary platform technology. Over the past several months, management has made significant progress moving the pipeline forward.
BriaCell Doses First Patient In Phase 1/2 Clinical Study With BriaVax
BriaCell Therapeutics remains one of my favorite under-the-radar immuno-oncology names. Finally, the CEO just invested $1.5 million of his own money into the story and that alone should warrant investor's attention.
How BioSig's PURE EP Beats The Competition
The market is asleep on BioSig right now. Perhaps they see an upstart player not capable of competing with behemoths like GE and J&J.
Why Radicava Approval Is Good News For BrainStorm Cell Therapeutics
BrainStorm is expanding its management team and focusing on securing non-dilutive capital. The company has the cash to begin the study and an excellent track record of bringing in non-dilutive grants to keep shareholder dilution to a minimum.
Should You Invest In Axsome Therapeutics?
Axsome has good insider ownership, plenty of cash, drugs with proven mechanisms of action, strong IP, and plenty of catalysts. Should it be in your portfolio?
RedHill's R&D Day Highlights Potential For Bekinda
RedHill Biopharma Ltd held an R&D Day highlighting for investors the clinical and commercial attributes of BEKINDA (RHB-102).
BioSig Provides Shareholder Letter - April 2017
The letter highlights some of the recent positive developments for the company, including the collaboration with Mayo Clinic and the recent $5.0 million financing.
NurOwn Shows Potential In Preclinical Autism Model
BrainStorm’s next step in the development of NurOwn is to initiate a Phase 3 clinical study in the U.S. This will be a major milestone for the company and establish an important Catalyst for the shares once initiated.
MabVax Posters Highlight Why I Like This Story
MSKCC continues to be an excellent clinical investigator for MabVax Therapeutics. Cash is perhaps the only missing piece to the story, which I expect management to address in the near future.
Let's Talk Depression And How To Play The NMDA Buzz
I think VistaGen's stock has tremendous upside potential that today's price. The company is likely to raise cash at some point over the next several months.
Yeliva Granted Orphan Drug Designation In Cholangiocarcinoma
I ultimately believe that RedHill will look to partner Yeliva for Phase 3 development, and RedHill is certainly well-funded today with $66 million on hand as of December 2016, but every bit of financial assistance helps.
1 to 16 of 54 Posts
1 2 3 4